CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.
News|Articles|November 1, 2026
FAQ: Diabetic eye disease awareness month 2026
Author(s)Kassi Filkins
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.
Advertisement
Advertisement
Prevent Blindness designates November as Diabetes-related Eye Disease Month.1 The 2026 observance arrives as an estimated 9.6 million people in the US live with diabetic retinopathy (DR), including 1.84 million with vision-threatening DR (VTDR).2,3 The questions below cover the screening gap, guideline updates, and recent trial data across DR and diabetic macular edema (DME).
Related to this article
Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.
IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
AREDS-based review links Mediterranean diet adherence to slower AMD and GA progression, as a complement to AREDS2 supplements.
Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
In the latest episode of The Wills Retina Report, Regillo and Ho discuss where gene therapy stands for retinal disease, from late-stage programs in neovascular age-related macular degeneration to earlier efforts in geographic atrophy and diabetic retinopathy.
Advertisement
Advertisement